Page 638 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

598 MEDICAMENT INDUISANT DES MODIFICATIONS COVALENTES DE L'ADN

BIBLIOGRAPHIE
MÉTHOTREXATE
SEEGER D., SMITH J. et HULTQUIST M., Antagonist for pteroylglutamic acid, J. Am.
Chem. Soc., 1947, 69, 2567; SEEGER D., COSULICH D., SMITH J., HULTQUIST M.,
Analogs of pteroylglutamic acid, J. Am. Chem. Soc., 1949, 71, 1753-1758.
AMERICAN CYANAMID, brevet US 2.512.572 (1950).
JOHNS D. et LOO T., Metabolite of 4-amino-4-deoxy-NO-methylpteroylglutamic acid,
J. Pharm. Sc., 1967, 56, 356-359.
TAYLOR E., Chemistry and bio/ogy ofpteridines. International Academic Printing, Tokyo,
1970.
LEE W., Methotrexate analogs containing spurious amino acids, J. Med. Chem., 1974,
17, 326-330.
POE M., Acidic dissociation constants of folie acid and methotrexate, J. Bio/. Chem.,
1977, 252, 3724-28.
CRAMER S., Occurrence and significance of D-methotrexate as a contaminant of com-
mercial methotrexate, Cancer Research, 1984, 44, 1843-1846.
HENDEL J., Enterohepatic cycling of methotrexate, Eur. J. Clin. Phamiaco/., 1984, 26,
103-107.
GIROUD J-P, MATHE G. et MEYNIEL G., Pharmacologie clinique, bases de la thérapeu-
tique, 1929-1932, Expansion Scientifique Française, Paris, 1988.
CONNORS K., Chemical stability of pharmaceuticals, 566-572, John Wiley, New York,
1989.
SCHWEITZER B., Dihydrofolate reductase as a therapeutic target, Faseb J., 1990, 4,
2441-2452.
NAKAMURA T., Clinical pharrnacology of anticancer agents, Gan to Kagaku Ryoho,
1992, 19, 409-420.
PELMONT J., Enzymes, 596-598, Presses Universitaires de Grenoble, 1995.
CHATELUT E., Adaptation de la posologie des anticancéreux, Revue française des labo-
ratoires, 1998, n° 304, 55-57.
RALTITREXED
JACKSON C. R, NIETHAMMER. D., Acquired methotrexate resistance in lymphoblastes
resulting from altered kinetic properties of dihydrofolate reductase. Eur. J. Cancer,
1977, 13, 567-575.
TEMPLE C. Jr. et al., Pyrido[2,3-d]pyrimidines. Synthesis of 5-deaza analogues of ami-
nopteridin, methotrexate, folic acid, and N'O-methylfolic acid, J. Org. Chem., 1982,
47, 761-764.
JACKSON C.R. et al., Biochemical affects of quinazoline inhibitor of thymidilate synthe-
tase, N-(4-(N-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-
L-glutamic acid (CB3717), on human lymphoblastoid cells, Biochem. Pharmacol.,
1983, 32, 3783-3790.
CALVERT A. et al., A phase I evaluation of the quinazoline antifolate thymidilate synthe-
tase inhibition, N-propargyl-5,8-dideazafolic acid and CB 3717., J. Clin. Oncol., 1986,
4, 1245-52.